Baylor College of Medicine

Other

Agennix Incorporated

Isis Pharmaceuticals, Inc.

Genetronics, Inc.

Strike Bio, Inc.

Bert W O'Malley

Orla M Conneely

David Michael Lonard

Denis R Headon

Ming-Jer Tsai

Gregory S May

Donald P McDonnell

Yongcheng Song

Sophia Yang Tsai

Jianming Xu

Elisabetta Vegeto

Robert J Schwartz

Jin Wang

Jianwei Chen

Franco J DeMayo

Sang Jun Han

William T Schrader

Bryan Nikolai

Prashi Jain

Yosef Gilad

Clifford Dacso

Fred D Ledley

Ronan F Power

C Frank Bennett

Lex M Cowsert

Donald Rao

John J Nemunaitis

Jason Fewell

Ronald V Abruzzese

Nicholas Mitsiades

Timothy Gerald Palzkill

Harry C Ledebur, Jr

Sean E Mcguire

Sergio Onate

Vidya Mehta

Lei Wang

Jeffrey L Nordstrom

Lee-Ho Wang

George Francis Allan

Xiaonan Li

Subhamoy Dasgupta

Arun Sreekumar

Joseph D Kittle, Jr

Small molecule stimulators of steroid receptor coactivator-3 (SRC-3) and methods of their use as cardioprotective agents are provided. The small molecule stimulators are useful for promoting cardiac protection and repair and vascular regeneration after myocardial infarction. The compounds are also useful in preventing cardiac hypertrophy and collagen deposition and improving cardiac post-infarction function.

Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents

The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration.

Targeting of SRC-3 in immune cells as an immunomodulatory therapeutic for the treatment of cancer

Small molecule stimulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing cancer. Also provided are methods for stimulating SRC family proteins in a cell.

Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer

Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.

Small molecule regulators of steroid receptor coactivators and methods of use thereof

Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.

SRC-2 use as metabolic biomarker for diagnosis and treatment of metastatic prostate cancer

The present invention includes compositions and methods for making and using a RNAi capable of reducing expression of two or more genes, comprising: a first RNAi molecule that reduces the expression of a first target gene; a second RNAi molecule that reduces the expression of the first or a second target gene; and optionally a third RNAi molecule that reduces the expression of the first, the second, or a third target gene, wherein the RNAi molecules reduce the expression level of, e.g., mutated KRAS, SRC-3, EGFR, PIK3, NCOA3, or ERalpha1, and can be, e.g., miRNAs, shRNAs, or bifunctional shRNAs.

Multiple targeted RNAI for the treatment of cancers

Disclosed is a novel inducible expression system characterized by undetectable biological effect in the absence of an inducer, but which exhibits efficient inducibility in the presence of an inducer.

Gene switch systems employing regulators with decreased dimerization

Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms

The present invention provides mutant proteins of steroid hormone receptors. These mutant proteins are useful in methods of distinguishing a steroid hormone receptor antagonist from a steroid hormone receptor agonist. The present invention also provides plasmids containing mutated steroid hormone receptor proteins and cells transfected with those plasmids. In addition, the present invention provides methods for determining whether a compound is a steroid hormone receptor antagonist or agonist. Also, the present invention provides methods of determining endogenous ligands for steroid hormone receptors. The invention further provides a molecular switch for regulating expression in gene therapy and methods of employing the molecular switch in humans, animals, transgenic animals and plants.

Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy

Growing community of inventors

Houston, TX, United States of America

Bert W O'Malley